Price Alert: Shares of Tabula Rasa HealthCare (TRHC) Trade 10.68% Lower at Midday June 22

Equities Staff  |

Tabula Rasa HealthCare Inc (NASDAQ: TRHC) has dropped $0.33 (10.68%) and is currently sitting at $2.77, as of 12:13:14 est on June 22.

522,898 shares have exchanged hands.

The Company has risen 2.66% over the last 5 days and shares have risen 34.35% over the last 30 days.

Tabula Rasa HealthCare anticipates its next earnings on 2022-08-04.

For technical charts, analysis, and more on Tabula Rasa HealthCare visit the company profile.

About Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare provides medication safety solutions that empower healthcare professionals to optimize medication regimens and reduce medication-related risk, specifically targeting adverse drug events. TRHC's technology solutions, including DoseMeRx™ and MedWise™, improve patient outcomes, reduce hospitalizations, and lower healthcare costs. TRHC's extensive clinical tele-pharmacy network improves care for patients nationwide. Its solutions are trusted by health plans and pharmacies to help drive value-based payment results.

To get more information on Tabula Rasa HealthCare Inc and to follow the company's latest updates, you can visit the company's profile page here: Tabula Rasa HealthCare Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content